tetano
Editor, Senior Moderator
Nat Biotechnol. 2012 Nov 25. doi: 10.1038/nbt.2436. [Epub ahead of print]
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.
Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, Kramps T.
Source
1] Institute of Immunology, Friedrich-Loeffler-Institut, T?bingen, Germany. [2] CureVac GmbH, T?bingen, Germany (B.P.); Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany (A.B.V. and L.S.). [3].
Abstract
Despite substantial improvements, influenza vaccine production-and availability-remain suboptimal. Influenza vaccines based on mRNA may offer a solution as sequence-matched, clinical-grade material could be produced reliably and rapidly in a scalable process, allowing quick response to the emergence of pandemic strains. Here we show that mRNA vaccines induce balanced, long-lived and protective immunity to influenza A virus infections in even very young and very old mice and that the vaccine remains protective upon thermal stress. This vaccine format elicits B and T cell-dependent protection and targets multiple antigens, including the highly conserved viral nucleoprotein, indicating its usefulness as a cross-protective vaccine. In ferrets and pigs, mRNA vaccines induce immunological correlates of protection and protective effects similar to those of a licensed influenza vaccine in pigs. Thus, mRNA vaccines could address substantial medical need in the area of influenza prophylaxis and the broader realm of anti-infective vaccinology.
PMID:
23159882
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23159882
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.
Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L, Kramps T.
Source
1] Institute of Immunology, Friedrich-Loeffler-Institut, T?bingen, Germany. [2] CureVac GmbH, T?bingen, Germany (B.P.); Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany (A.B.V. and L.S.). [3].
Abstract
Despite substantial improvements, influenza vaccine production-and availability-remain suboptimal. Influenza vaccines based on mRNA may offer a solution as sequence-matched, clinical-grade material could be produced reliably and rapidly in a scalable process, allowing quick response to the emergence of pandemic strains. Here we show that mRNA vaccines induce balanced, long-lived and protective immunity to influenza A virus infections in even very young and very old mice and that the vaccine remains protective upon thermal stress. This vaccine format elicits B and T cell-dependent protection and targets multiple antigens, including the highly conserved viral nucleoprotein, indicating its usefulness as a cross-protective vaccine. In ferrets and pigs, mRNA vaccines induce immunological correlates of protection and protective effects similar to those of a licensed influenza vaccine in pigs. Thus, mRNA vaccines could address substantial medical need in the area of influenza prophylaxis and the broader realm of anti-infective vaccinology.
PMID:
23159882
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23159882